Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Food on BN104 Pharmacokinetics
NCT06724549Phase 1Completed
- Sponsor
- BioNova Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vicrimenib in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) (2 arms), sponsored by BioNova Pharmaceuticals. Primary endpoints: Peak Concentration at 2 weeks, Area Under the Curve to Last Measurable Concentration at 2 weeks and 1 more. Started Jan 2025; status: completed.
02
Drugs
vicrimenib
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT06724549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06724549.